ADAP
Price
$0.08
Change
-$0.00 (-0.00%)
Updated
Sep 17, 12:09 PM (EDT)
Capitalization
21.68M
49 days until earnings call
KRYS
Price
$155.22
Change
+$0.84 (+0.54%)
Updated
Sep 17, 12:28 PM (EDT)
Capitalization
4.51B
54 days until earnings call
Interact to see
Advertisement

ADAP vs KRYS

Header iconADAP vs KRYS Comparison
Open Charts ADAP vs KRYSBanner chart's image
Adaptimmune Therapeutics
Price$0.08
Change-$0.00 (-0.00%)
Volume$4.94K
Capitalization21.68M
Krystal Biotech
Price$155.22
Change+$0.84 (+0.54%)
Volume$100
Capitalization4.51B
ADAP vs KRYS Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. KRYS commentary
Sep 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and KRYS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 17, 2025
Stock price -- (ADAP: $0.08 vs. KRYS: $154.38)
Brand notoriety: ADAP and KRYS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 741% vs. KRYS: 109%
Market capitalization -- ADAP: $21.68M vs. KRYS: $4.51B
ADAP [@Biotechnology] is valued at $21.68M. KRYS’s [@Biotechnology] market capitalization is $4.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $100.82B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileKRYS’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • KRYS’s FA Score: 0 green, 5 red.
According to our system of comparison, KRYS is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while KRYS’s TA Score has 6 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 4 bearish.
  • KRYS’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а +66.26% price change this week, while KRYS (@Biotechnology) price change was +9.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.37%. For the same industry, the average monthly price growth was +6.95%, and the average quarterly price growth was +36.10%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

KRYS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+3.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($4.51B) has a higher market cap than ADAP($21.7M). KRYS YTD gains are higher at: -1.455 vs. ADAP (-84.815). KRYS has higher annual earnings (EBITDA): 158M vs. ADAP (-149.75M). KRYS has more cash in the bank: 682M vs. ADAP (26.1M). KRYS has less debt than ADAP: KRYS (9.68M) vs ADAP (48.7M). KRYS has higher revenues than ADAP: KRYS (359M) vs ADAP (65.1M).
ADAPKRYSADAP / KRYS
Capitalization21.7M4.51B0%
EBITDA-149.75M158M-95%
Gain YTD-84.815-1.4555,828%
P/E RatioN/A31.38-
Revenue65.1M359M18%
Total Cash26.1M682M4%
Total Debt48.7M9.68M503%
FUNDAMENTALS RATINGS
ADAP vs KRYS: Fundamental Ratings
ADAP
KRYS
OUTLOOK RATING
1..100
2768
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
65
Fair valued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
10053
PRICE GROWTH RATING
1..100
6558
P/E GROWTH RATING
1..100
10087
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (47) in the Biotechnology industry is in the same range as KRYS (65) in the Pharmaceuticals Major industry. This means that ADAP’s stock grew similarly to KRYS’s over the last 12 months.

KRYS's Profit vs Risk Rating (39) in the Pharmaceuticals Major industry is somewhat better than the same rating for ADAP (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ADAP’s over the last 12 months.

KRYS's SMR Rating (53) in the Pharmaceuticals Major industry is somewhat better than the same rating for ADAP (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than ADAP’s over the last 12 months.

KRYS's Price Growth Rating (58) in the Pharmaceuticals Major industry is in the same range as ADAP (65) in the Biotechnology industry. This means that KRYS’s stock grew similarly to ADAP’s over the last 12 months.

KRYS's P/E Growth Rating (87) in the Pharmaceuticals Major industry is in the same range as ADAP (100) in the Biotechnology industry. This means that KRYS’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPKRYS
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 13 days ago
90%
Bearish Trend 8 days ago
75%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TAOX6.030.08
+1.34%
Tao Synergies Inc
TRDA5.120.06
+1.19%
Entrada Therapeutics
SNDR24.080.16
+0.67%
Schneider National
EA172.080.32
+0.18%
Electronic Arts
THS17.37-0.06
-0.34%
Treehouse Foods

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with NEVPF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+22.82%
NEVPF - ADAP
56%
Loosely correlated
N/A
AKBA - ADAP
41%
Loosely correlated
-3.08%
ORMP - ADAP
36%
Loosely correlated
-1.29%
CSLLY - ADAP
32%
Poorly correlated
-0.84%
AXON - ADAP
31%
Poorly correlated
-1.33%
More

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
-0.85%
XNCR - KRYS
51%
Loosely correlated
+1.53%
CRNX - KRYS
49%
Loosely correlated
+0.98%
ACLX - KRYS
49%
Loosely correlated
+2.86%
CGON - KRYS
48%
Loosely correlated
+3.35%
SYRE - KRYS
48%
Loosely correlated
-0.13%
More